text_1: Biogen's secret campaign to bring its Alzheimer's drug back from the ashes.
text_2: Biogen Inc’s (BIIB.O) shock decision this week to bring its experimental Alzheimer’s drug back from the scrap heap was born out of “top secret” meetings, non-disclosure agreements and six months of hashing over trial data with scientists, regulators and statisticians, researchers told Reuters.